Mingqian Feng

Wuhan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Correction: A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

Correction: A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

Journal: Frontiers in immunology

Published: August 07, 2026

The microbiome-EBV axis in carcinogenesis bridges commensal influence and viral oncogenesis.

The microbiome-EBV axis in carcinogenesis bridges commensal influence and viral oncogenesis.

Journal: Frontiers in immunology

Published: June 15, 2026

A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

Journal: Frontiers in immunology

Published: June 12, 2026

Construction and Application of a Canine SLAM Receptor-Based System from Vero Cell Line to Virus Isolation and Parallel Antibody Screening.

Construction and Application of a Canine SLAM Receptor-Based System from Vero Cell Line to Virus Isolation and Parallel Antibody Screening.

Journal: International journal of molecular sciences

Published: January 05, 2026

VidComposition: Can MLLMs Analyze Compositions in Compiled Videos?

VidComposition: Can MLLMs Analyze Compositions in Compiled Videos?

Journal: Proceedings. IEEE Computer Society Conference on Computer Vision and Pattern Recognition

Published: September 08, 2025

Dual T/NK cell engagement via B7-H6-targeted bispecific antibodies and IL-15 eradicates chemo-resistant solid tumors.

Dual T/NK cell engagement via B7-H6-targeted bispecific antibodies and IL-15 eradicates chemo-resistant solid tumors.

Journal: Frontiers in immunology

Published: May 09, 2025

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody.

Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody.

Journal: Frontiers in immunology

Published: March 25, 2025

Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer.

Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer.

Journal: Frontiers in immunology

Published: March 12, 2025

Dietary nutrient intake and cancer presence: evidence from a cross-sectional study.

Dietary nutrient intake and cancer presence: evidence from a cross-sectional study.

Journal: Frontiers in nutrition

Published: December 26, 2024

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer.

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer.

Journal: Frontiers in immunology

Published: November 08, 2024

A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma.

A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma.

Journal: Frontiers in immunology

Published: October 10, 2024

YEATS2: a novel cancer epigenetic reader and potential therapeutic target.

YEATS2: a novel cancer epigenetic reader and potential therapeutic target.

Journal: Cancer cell international

Published: September 28, 2024

Showing 1-12 of 37

Last Updated: 09/26/2026